A case report of hydroxychloroquine-induced auditory and visual hallucination.
Identifieur interne : 000834 ( Main/Corpus ); précédent : 000833; suivant : 000835A case report of hydroxychloroquine-induced auditory and visual hallucination.
Auteurs : Zakiye Ganjei ; Kiumars BahmaniSource :
- International journal of clinical pharmacology and therapeutics [ 0946-1965 ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Hydroxychloroquine.
- chemically induced : Hallucinations.
- drug therapy : COVID-19.
- Adult, Female, Humans, SARS-CoV-2.
Abstract
INTRODUCTION
Discoid lupus erythematosus (DLE) is a common manifestation of lupus erythematosus. Hydroxychloroquine is commonly used in the treatment of lupus erythematosus. The present study aims to report hallucinations induced by hydroxychloroquine.
CASE PRESENTATION
A 37-year-old woman came to the dermatology clinic with a complaint of a red lesion on her left cheek. Physical examination revealed an ulcerative erythematous plaque with keratotic scales, an atrophic area of ~ 2 × 2.5 cm. Biopsy of the lesion was performed, and histopathology result was consistent with the diagnosis of DLE. Laboratory tests were all normal. Topical clobetasol and pimecrolimus were prescribed for the patient, who was recommended to use sunscreen as well. However, the treatment did not work, thus hydroxychloroquine 200 mg daily was added to the treatment. After a week, the patient came back to the clinic with her husband with the complaint of auditory and visual hallucinations, nightmares, and occasional decrease in consciousness level. After neurology and psychiatric consultation, hydroxychloroquine was discontinued and replaced with intralesional administration of triamcinolone. The lesion disappeared and did not recur.
DISCUSSION
Previous studies and the lack of another explanation for the patient's hallucinations imply a strong correlation between hydroxychloroquine and hallucinations. The mechanism of these side effects has not been fully elucidated. However, this side effect has only been reported in cases of connective tissue diseases. As currently hydroxychloroquine is widely used in the treatment of COVID-19 and other diseases, its potential risk of psychiatric complications should be considered in clinical practice.
DOI: 10.5414/CP203789
PubMed: 33191905
Links to Exploration step
pubmed:33191905Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A case report of hydroxychloroquine-induced auditory and visual hallucination.</title>
<author><name sortKey="Ganjei, Zakiye" sort="Ganjei, Zakiye" uniqKey="Ganjei Z" first="Zakiye" last="Ganjei">Zakiye Ganjei</name>
</author>
<author><name sortKey="Bahmani, Kiumars" sort="Bahmani, Kiumars" uniqKey="Bahmani K" first="Kiumars" last="Bahmani">Kiumars Bahmani</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33191905</idno>
<idno type="pmid">33191905</idno>
<idno type="doi">10.5414/CP203789</idno>
<idno type="wicri:Area/Main/Corpus">000834</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000834</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A case report of hydroxychloroquine-induced auditory and visual hallucination.</title>
<author><name sortKey="Ganjei, Zakiye" sort="Ganjei, Zakiye" uniqKey="Ganjei Z" first="Zakiye" last="Ganjei">Zakiye Ganjei</name>
</author>
<author><name sortKey="Bahmani, Kiumars" sort="Bahmani, Kiumars" uniqKey="Bahmani K" first="Kiumars" last="Bahmani">Kiumars Bahmani</name>
</author>
</analytic>
<series><title level="j">International journal of clinical pharmacology and therapeutics</title>
<idno type="ISSN">0946-1965</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>COVID-19 (drug therapy)</term>
<term>Female (MeSH)</term>
<term>Hallucinations (chemically induced)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b>
</p>
<p>Discoid lupus erythematosus (DLE) is a common manifestation of lupus erythematosus. Hydroxychloroquine is commonly used in the treatment of lupus erythematosus. The present study aims to report hallucinations induced by hydroxychloroquine.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CASE PRESENTATION</b>
</p>
<p>A 37-year-old woman came to the dermatology clinic with a complaint of a red lesion on her left cheek. Physical examination revealed an ulcerative erythematous plaque with keratotic scales, an atrophic area of ~ 2 × 2.5 cm. Biopsy of the lesion was performed, and histopathology result was consistent with the diagnosis of DLE. Laboratory tests were all normal. Topical clobetasol and pimecrolimus were prescribed for the patient, who was recommended to use sunscreen as well. However, the treatment did not work, thus hydroxychloroquine 200 mg daily was added to the treatment. After a week, the patient came back to the clinic with her husband with the complaint of auditory and visual hallucinations, nightmares, and occasional decrease in consciousness level. After neurology and psychiatric consultation, hydroxychloroquine was discontinued and replaced with intralesional administration of triamcinolone. The lesion disappeared and did not recur.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DISCUSSION</b>
</p>
<p>Previous studies and the lack of another explanation for the patient's hallucinations imply a strong correlation between hydroxychloroquine and hallucinations. The mechanism of these side effects has not been fully elucidated. However, this side effect has only been reported in cases of connective tissue diseases. As currently hydroxychloroquine is widely used in the treatment of COVID-19 and other diseases, its potential risk of psychiatric complications should be considered in clinical practice.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33191905</PMID>
<DateCompleted><Year>2021</Year>
<Month>04</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0946-1965</ISSN>
<JournalIssue CitedMedium="Print"><Volume>59</Volume>
<Issue>3</Issue>
<PubDate><Year>2021</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>International journal of clinical pharmacology and therapeutics</Title>
<ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>A case report of hydroxychloroquine-induced auditory and visual hallucination.</ArticleTitle>
<Pagination><MedlinePgn>254-256</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.5414/CP203789</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Discoid lupus erythematosus (DLE) is a common manifestation of lupus erythematosus. Hydroxychloroquine is commonly used in the treatment of lupus erythematosus. The present study aims to report hallucinations induced by hydroxychloroquine.</AbstractText>
<AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 37-year-old woman came to the dermatology clinic with a complaint of a red lesion on her left cheek. Physical examination revealed an ulcerative erythematous plaque with keratotic scales, an atrophic area of ~ 2 × 2.5 cm. Biopsy of the lesion was performed, and histopathology result was consistent with the diagnosis of DLE. Laboratory tests were all normal. Topical clobetasol and pimecrolimus were prescribed for the patient, who was recommended to use sunscreen as well. However, the treatment did not work, thus hydroxychloroquine 200 mg daily was added to the treatment. After a week, the patient came back to the clinic with her husband with the complaint of auditory and visual hallucinations, nightmares, and occasional decrease in consciousness level. After neurology and psychiatric consultation, hydroxychloroquine was discontinued and replaced with intralesional administration of triamcinolone. The lesion disappeared and did not recur.</AbstractText>
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Previous studies and the lack of another explanation for the patient's hallucinations imply a strong correlation between hydroxychloroquine and hallucinations. The mechanism of these side effects has not been fully elucidated. However, this side effect has only been reported in cases of connective tissue diseases. As currently hydroxychloroquine is widely used in the treatment of COVID-19 and other diseases, its potential risk of psychiatric complications should be considered in clinical practice.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ganjei</LastName>
<ForeName>Zakiye</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bahmani</LastName>
<ForeName>Kiumars</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Int J Clin Pharmacol Ther</MedlineTA>
<NlmUniqueID>9423309</NlmUniqueID>
<ISSNLinking>0946-1965</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year>
<Month>02</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>16</Day>
<Hour>8</Hour>
<Minute>42</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33191905</ArticleId>
<ArticleId IdType="pii">187451</ArticleId>
<ArticleId IdType="doi">10.5414/CP203789</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33191905 |texte= A case report of hydroxychloroquine-induced auditory and visual hallucination. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33191905" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |